CLASSIFICATION: PEPTIDE HORMONE
ACTIVE SUBSTANCE: GHK-CU
FORM: 2 ML VIAL x 50 MG
ACTIVE HALF-LIFE: N/A
DOSAGE: MEN N/A
ACNE: N/A
WATER RETENTION: N/A
HBR: N/A
HEPATOTOXICITY: N/A
AROMATIZATION: N/A
MANUFACTURER: AXIOLABS
Axiolabs GHK-CU 50 mg is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that has garnered significant attention in wound healing and tissue regeneration research. Each 2 mL vial contains 50 mg of lyophilized GHK-CU, ready for reconstitution with bacteriostatic water for laboratory studies.
This peptide is recognized for its ability to modulate gene expression related to tissue repair, inflammation, and collagen production. For researchers investigating dermal regeneration or systemic tissue recovery, GHK-CU offers a unique copper-dependent mechanism distinct from other repair-focused peptides. Explore similar research compounds like BPC 157 5 mg or TB 500 5 mg.
Unlike many synthetic peptides, GHK-CU is a matrikine — a peptide fragment naturally released during tissue injury that signals repair processes. Its copper-binding capacity is essential for its biological activity, influencing copper-dependent enzymes involved in extracellular matrix remodeling and antioxidant defense.
For performance-focused research, GHK-CU is often studied alongside Ipamorelin 5 mg to evaluate combined effects on recovery and tissue integrity. The 50 mg dosage provides ample material for extended research protocols or multi-subject studies.
Axiolabs GHK-CU 50 mg is intended for laboratory research only. Not for human consumption or clinical use.
External research on GHK-CU's mechanisms can be explored via PubMed for peer-reviewed studies.
For laboratory research use only. Not for human consumption. Reconstitution and handling must be performed by qualified personnel using sterile techniques.
The standard reconstitution yields a concentration of approximately 10-25 mg/mL depending on the volume used. For precise dosing, researchers should calculate based on desired mg per injection volume.
In animal models and in vitro studies, GHK-CU is often administered at dosages ranging from 1-2 mg per day for systemic research. For topical studies, concentrations of 0.5-2% are commonly investigated. Subcutaneous injection near the site of interest is typical for localized tissue studies.
GHK-CU is frequently studied alongside BPC-157 for synergistic effects on tissue repair and collagen synthesis. For stacking in research protocols, BPC 157 5 mg can be reconstituted and administered on an alternating schedule.
Note: Dosages mentioned are for research purposes only. Individual response varies in animal models. Always follow institutional animal care guidelines when conducting in vivo research.
Third-party analytical testing (COA) for Axiolabs GHK-CU 50 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.
This product is supplied through the official Axiolabs distribution chain and shipped in original manufacturer packaging. The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Store Axiolabs GHK-CU 50 mg lyophilized powder in a cool, dry place away from direct light and moisture. Prior to reconstitution, the unopened vial should be kept at controlled room temperature (15-25°C) or refrigerated (2-8°C) for long-term storage. Do not freeze the lyophilized powder, as this may damage the peptide structure.
After reconstitution with bacteriostatic water, the solution must be stored at 2-8°C (refrigerator) and used within 30 days to maintain peptide integrity. The solution will have a characteristic blue tint due to copper content — this is normal. Avoid repeated freeze-thaw cycles. Do not use if the solution appears cloudy or contains particulates, or if the vial seal is compromised.
Keep out of reach of children and unauthorized personnel. Follow standard laboratory safety protocols when handling peptides.
Proper storage conditions help maintain research-grade purity and consistent performance across the product's shelf life.
GHK-CU is studied for its role in wound healing, tissue regeneration, collagen synthesis, and anti-inflammatory effects in animal models and in vitro systems. It is a naturally occurring copper-binding peptide.
Add 2-5 mL of bacteriostatic water to the 50 mg vial, swirling gently until fully dissolved. The resulting concentration will be approximately 10-25 mg/mL depending on the volume used.
In animal studies, dosages often range from 1-2 mg per day for subcutaneous administration. For topical research, concentrations of 0.5-2% are commonly investigated.
Yes. GHK-CU is commonly studied alongside BPC-157 for synergistic effects on tissue repair and collagen remodeling. It may also be combined with TB-500 in comprehensive healing research protocols.
Third-party COA testing is currently pending. Axiolabs is committed to publishing batch-specific lab reports as soon as analytical testing is completed and verified.
Please log in to write GHK-CU 50 MG review.
CLASSIFICATION: COPPER PEPTIDE COMPLEX
ACTIVE SUBSTANCE: GHK-CU (GLY-HIS-LYS COPPER PEPTIDE)
FORM: 2 ML VIAL x 50 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: APPROXIMATELY 2-3 HOURS
DOSAGE: 1-3 MG PER DAY (SUBCUTANEOUS OR TOPICAL)
ACNE: NO RISK
WATER RETENTION: NO RISK
HIGH BLOOD PRESSURE (HBP): NO RISK
HEPATOTOXICITY: NO RISK
AROMATIZATION: DOES NOT AROMATIZE
MANUFACTURER: DRAGON PHARMA
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: SERM (SELECTIVE ESTROGEN RECEPTOR MODULATOR)
ACTIVE SUBSTANCE: CLOMIPHENE CITRATE
FORM: 50 TABLETS x 50 MG
ACTIVE HALF-LIFE: 5-7 DAYS
DOSAGE: MEN 25–100 MG/DAY
ACNE: UNLIKELY
WATER RETENTION: NONE
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: LOW
AROMATIZATION: NO
MANUFACTURER: AXIOLABS
CLASSIFICATION: AROMATASE INHIBITOR; ANTIESTROGEN
ACTIVE SUBSTANCE: ANASTROZOLE
FORM: 50 TABLETS x 1 MG
ACTIVE HALF-LIFE: ~48 HOURS
DOSAGE: 0.5–1 MG EVERY OTHER DAY
ACNE: REDUCED
WATER RETENTION: SIGNIFICANTLY REDUCED
HIGH BLOOD PRESSURE (HBP): DECREASED RISK
HEPATOTOXICITY: NO
AROMATIZATION: BLOCKED
MANUFACTURER: AXIOLABS
CLASSIFICATION: AROMATASE INHIBITOR; ANTIESTROGEN
ACTIVE SUBSTANCE: EXEMESTANE
FORM: 50 TABLETS x 25 MG
ACTIVE HALF-LIFE: ~24 HOURS
DOSAGE: 12.5–25 MG/DAY OR EOD
ACNE: REDUCED
WATER RETENTION: SIGNIFICANTLY REDUCED
HIGH BLOOD PRESSURE (HBP): REDUCED RISK
HEPATOTOXICITY: NO
AROMATIZATION: PERMANENTLY BLOCKED
MANUFACTURER: AXIOLABS
CLASSIFICATION: ANDROGEN; ANABOLIC STEROID; PROGESTOGEN
ACTIVE SUBSTANCE: NANDROLONE DECANOATE
FORM: 10 ML VIAL x 250 MG/ML
ACTIVE HALF-LIFE: ~15 DAYS
DOSAGE: 250–600 MG/WEEK
ACNE: POSSIBLE
WATER RETENTION: MODERATE
HIGH BLOOD PRESSURE (HBP): POSSIBLE
HEPATOTOXICITY: NO
AROMATIZATION: LOW (PROGESTIN ACTIVITY)
MANUFACTURER: AXIOLABS
CLASSIFICATION: ANDROGEN; ANABOLIC STEROID
ACTIVE SUBSTANCES:
- 50 MG DROSTANOLONE PROPIONATE
- 50 MG TESTOSTERONE PROPIONATE
- 50 MG TRENBOLONE ACETATE
FORM: 10 ML VIAL x 150 MG/ML
ACTIVE HALF-LIFE: ~1–2 DAYS
DOSAGE: MEN 300–600 MG PER WEEK
ACNE: YES
WATER RETENTION: LOW
HIGH BLOOD PRESSURE (HBP): POSSIBLE
HEPATOTOXICITY: NO
AROMATIZATION: LOW (FROM TESTOSTERONE)
MANUFACTURER: AXIOLABS